PHAT

Business Context and Reporting Period

Company: Phathom Pharmaceuticals, Inc. (PHAT)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Phathom is a commercial-stage biopharmaceutical company focused on gastrointestinal (GI) diseases. Its primary revenue source is the U.S. commercialization of VOQUEZNA (vonoprazan), a potassium-competitive acid blocker (PCAB), and its co-packaged formulations (VOQUEZNA DUAL PAK and VOQUEZNA TRIPLE PAK) for the treatment of Erosive GERD, Non-Erosive GERD, and H. pylori infection. The company holds exclusive U.S., European, and Canadian rights to vonoprazan via a license from Takeda Pharmaceutical Company Limited.

Key Financial Metrics

Note: The filing text does not provide a specific "Cash Flow from Operations" line item in the summary tables, but the Statement of Cash Flows indicates net cash used in operating activities was $166.8 million for 2025.

Material Changes vs. Prior Period

• Revenue Growth: Net product revenue increased by $119.9 million (217%) year-over-year, driven by expanded commercialization of VOQUEZNA for GERD and H. pylori indications and the July 2024 FDA approval for Non-Erosive GERD.
• Profitability Improvement: Net loss narrowed by $113.1 million to $221.2 million, primarily due to significant revenue growth outpacing the reduction in operating expenses.
• Operating Expenses: Total operating expenses decreased by $12.2 million to $312.5 million. Selling, General, and Administrative (SG&A) expenses declined by $11.0 million due to reduced promotional expenses, partially offset by $7.3 million in restructuring charges. Research and Development (R&D) expenses decreased by $1.3 million.
• Restructuring: In May 2025, the company implemented a cost reduction plan, reducing the workforce by 26 employees (approx. 6%) and incurring $9.2 million in restructuring charges.
• Regulatory Milestone: In June 2025, the FDA granted a citizen petition extending the New Chemical Entity (NCE) exclusivity for VOQUEZNA tablets to match the Dual and Triple Pak formulations, securing exclusivity through May 3, 2032.

Guidance, Outlook, and Risks

Outlook and Guidance: Management anticipates reaching operating profitability (excluding stock-based compensation) beginning in the third quarter of 2026. This projection assumes existing cash, anticipated product revenues, and net proceeds of $122.2 million from a January 2026 equity offering are sufficient to fund operations for at least the next 12 months.

Management Commentary: The company continues to execute its U.S. commercial strategy, with over 1.1 million prescriptions filled since launch. Commercial coverage exceeds 80% of U.S. commercial lives. In Q4 2025, Phathom initiated a Phase 2 clinical trial for vonoprazan in the treatment of eosinophilic esophagitis (EoE).

Key Risks and Contingencies:

• Liquidity and Capital Needs: The company has an accumulated deficit of $1.5 billion and relies on future revenue growth and potential additional financing to sustain operations and achieve profitability.
• Debt Obligations: Significant debt includes a Loan Agreement with Hercules Capital (amended in Feb 2026 to include a new $175 million tranche) and a Revenue Interest Financing Agreement requiring royalty payments on net sales (10% rate, subject to step-downs) until 200% of the investment amount is repaid.
• Supply Chain: Reliance on third-party manufacturers (Evonik, Catalent, Sandoz). A potential disruption in the supply of clarithromycin (a component of VOQUEZNA TRIPLE PAK) was noted, though no near-term disruption is currently anticipated.
• Competition: VOQUEZNA competes with generic Proton Pump Inhibitors (PPIs) and emerging PCABs (e.g., tegoprazan, fexuprazan) in development or approved in other markets.
• Regulatory and Pricing: Risks related to the Inflation Reduction Act (IRA), potential Medicaid funding reductions under the "One Big Beautiful Bill Act" (enacted July 2025), and payer utilization management (e.g., step therapy requirements).

Investor Verification Checklist

• Profitability Timeline: Verify the assumptions underlying the Q3 2026 operating profitability target, specifically the projected revenue growth rate required to offset fixed costs and debt service.
• Debt Covenants: Review the specific financial covenants in the amended Hercules Loan Agreement (e.g., minimum cash balance, trailing revenue thresholds) to assess the risk of default if revenue growth slows.
• Revenue Quality: Analyze the composition of net revenue, specifically the magnitude of rebates, chargebacks, and co-pay assistance accruals, which significantly impact net sales figures.
• Supply Chain Resilience: Confirm the status of the clarithromycin supply chain for VOQUEZNA TRIPLE PAK and the company's contingency plans for single-source manufacturing dependencies.
• Exclusivity Status: Confirm the effective date and scope of the extended NCE exclusivity through May 2032 and monitor for any generic challenges or patent litigation.
• Cash Burn Rate: Assess the current cash burn rate against the $130 million cash balance and the $122.2 million raised in January 2026 to determine the runway without further capital raises.